Vir Biotechnology Inc. (VIR)
NASDAQ: VIR
· Real-Time Price · USD
5.73
0.07 (1.24%)
At close: Oct 03, 2025, 3:59 PM
5.79
1.05%
After-hours: Oct 03, 2025, 07:51 PM EDT
Vir Biotechnology Revenue Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Collaboration Revenue Revenue | -495K | -70K | 8.32M | 1.39M | 55K | 52.19M | n/a | -4.39M | 16.52M | 46.57M | 21.61M | 309.14M | -54.94M | 1.23B | 809.46M | 102.4M | 5.33M | 605K | 200K | 609K | 237K |
| Collaboration Revenue Revenue Growth | +607.14% | -100.84% | +498.42% | +2429.09% | -99.89% | n/a | -100.00% | -126.56% | -64.53% | +115.53% | -93.01% | -662.69% | -104.47% | +51.91% | +690.51% | +1820.08% | +781.49% | +202.50% | -67.16% | +156.96% | n/a |
| Contract Revenue Revenue | 1.53M | 1.86M | 865K | 2.09M | 886K | 5.17M | 744K | 289K | 1.06M | 138K | 180K | 40M | 12.25M | 282K | 293K | 315K | n/a | n/a | n/a | n/a | n/a |
| Contract Revenue Revenue Growth | -18.13% | +115.49% | -58.63% | +136.00% | -82.87% | +595.16% | +157.44% | -72.66% | +665.94% | -23.33% | -99.55% | +226.41% | +4245.39% | -3.75% | -6.98% | n/a | n/a | n/a | n/a | n/a | n/a |
| Grant Revenue | 183K | 1.24M | 1.1M | n/a | 2.13M | n/a | 23.43M | 6.74M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Grant Revenue Growth | -85.22% | +12.96% | n/a | n/a | n/a | n/a | +247.78% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Revenue by Geography
| Period Ending | Jun 30, 2025 | Mar 31, 2025 |
|---|---|---|
| Non-Us Revenue | 1.53M | 1.86M |
| Non-Us Revenue Growth | -18.13% | n/a |
| United States Revenue | 183K | 1.24M |
| United States Revenue Growth | -85.22% | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 22.28M | 23.94M | 26.7M | 25.74M | 30.27M | 36.27M | 39.09M | 41.08M | 47.1M | 46.78M | 38.74M | 43.17M | 41.59M | 38.26M | 55.78M | 50.5M | 28.78M | 25.74M | 23.04M | 18.86M | 16.39M | 12.65M | 11.81M | 9.22M | 8.01M | 8.56M | 7.95M | 7.39M | 6.89M | 6.89M |
| Selling, General, and Administrative Revenue Growth | -6.94% | -10.33% | +3.72% | -14.94% | -16.56% | -7.21% | -4.84% | -12.78% | +0.69% | +20.74% | -10.26% | +3.81% | +8.72% | -31.41% | +10.46% | +75.45% | +11.82% | +11.70% | +22.19% | +15.09% | +29.54% | +7.13% | +28.06% | +15.09% | -6.40% | +7.67% | +7.51% | +7.25% | 0.00% | n/a |
| Research and Development Revenue | 97.51M | 118.64M | 106.08M | 195.18M | 97.86M | 68.01M | 89.54M | 148.25M | 171.86M | 157.64M | 155.17M | 114.17M | 115.08M | 90.23M | 128.34M | 98.67M | 86.13M | 134.87M | 87.09M | 70.68M | 79.65M | 64.98M | 52.93M | 39.86M | 29.8M | 25.87M | 21.97M | 29.84M | 24.21M | 24.21M |
| Research and Development Revenue Growth | -17.81% | +11.84% | -45.65% | +99.44% | +43.90% | -24.04% | -39.61% | -13.74% | +9.02% | +1.59% | +35.92% | -0.80% | +27.55% | -29.70% | +30.07% | +14.56% | -36.14% | +54.85% | +23.22% | -11.26% | +22.58% | +22.76% | +32.78% | +33.75% | +15.20% | +17.74% | -26.36% | +23.25% | 0.00% | n/a |